IPP Bureau
Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
By IPP Bureau - January 19, 2025
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Glenmark Life Sciences rebranded as Alivus Life Sciences
By IPP Bureau - January 19, 2025
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
GCPB revokes closure order of Aarti Pharmalabs’s Vapi plant
By IPP Bureau - January 19, 2025
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
Heraeus acquires Umicore’s Platinum API business outside of South America
By IPP Bureau - January 19, 2025
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Caplin Steriles gets USFDA approval for Levetiracetam in Sodium Chloride Injection Infusion bags
By IPP Bureau - January 18, 2025
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles
Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution
By IPP Bureau - January 18, 2025
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer
By IPP Bureau - January 18, 2025
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Calquence combination approved in US for untreated mantle cell lymphoma
By IPP Bureau - January 18, 2025
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
AstraZeneca receives CDSCO approval to launch eculizumab in India
By IPP Bureau - January 17, 2025
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Bajaj Healthcare receives exclusive rights for manufacturing, distribution & sales of finished formulation of Magnesium L Threonate
By IPP Bureau - January 17, 2025
The brand Magtein by Threotech has a sales value of approximately US $438 million
FDA issues five observations to Jubilant Pharmova’s Salisbury facility in USA
By IPP Bureau - January 17, 2025
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
Sun Pharma to acquire 100% stake in Antibe Therapeutics
By IPP Bureau - January 17, 2025
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
By IPP Bureau - January 17, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Alleima completes the acquisition of medical components firm Endox
By IPP Bureau - January 16, 2025
In 2023, Endox had revenues of approximately SEK 65 million
Dr. Kathiresan Rajasekar appointed President – International Business, Gufic Biosciences
By IPP Bureau - January 16, 2025
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
